These results demonstrate that DLGAP5 expression is closely associated with GEM sensitivity in BLCA, with higher DLGAP5 levels contributing to chemotherapy resistance in both mouse model and patients. Here, DLGAP5 is linked to bladder transitional cell carcinoma.